This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Acceleron Pharma (XLRN)
by Zacks Equity Research
Acceleron Pharma (XLRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Earnings Preview: Acceleron Pharma (XLRN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Beats on Q3 Earnings & Sales, Ups 2021 View
by Zacks Equity Research
Merck (MRK) beats Q3 estimates for earnings and sales. It raises financial guidance for 2021. The stock moves up in the pre-market trading session.
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.
Core PCE Inflation Stays at Record-High in August
by Zacks Equity Research
Core PCE Inflation Stays at Record-High in August.
Merck (MRK) Develops Pill to Lessen Covid Symptoms
by Mark Vickery
Results of a trial developed with Cambridge, MA-based Ridgeback Biotherapeutics are positive for an oral antiviral treatment for Covid-19.
Merck (MRK) to Acquire Acceleron, Build Rare Disease Portfolio
by Zacks Equity Research
Merck (MRK) is set to acquire rare diseases-focused company Acceleron Pharma for $11.5 billion and gain access to its promising phase III candidate.
Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week.
Acceleron (XLRN) Stock Up on Takeover Rumors for $11 Billion
by Zacks Equity Research
Acceleron (XLRN) up on rumors of a potential acquisition by a pharma giant for $11 billion or $180 per share.
Acceleron (XLRN) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Acceleron (XLRN) reports a wider loss in the second quarter of 2021 on higher costs and lower revenues.
Acceleron Pharma (XLRN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Acceleron (XLRN) delivered earnings and revenue surprises of -14.13% and -10.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Acceleron Pharma (XLRN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Acceleron (XLRN) delivered earnings and revenue surprises of 7.23% and -9.62%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Acceleron Pharma (XLRN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Acceleron (XLRN) Up 0.5% Since Last Earnings Report?
by Zacks Equity Research
Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acceleron (XLRN) Stock Jumps 3.3%: Will It Continue to Soar?
by Zacks Equity Research
Acceleron (XLRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Acceleron (XLRN) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
During Novavax's (NVAX) upcoming fourth-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
What's in the Cards for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) fourth-quarter earnings call, investors are likely to focus on sales number for its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.
Inovio (INO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.
Analysts Estimate Acceleron Pharma (XLRN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals
5 Biotech Stocks That More Than Doubled This Year
by Ekta Bagri
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
5 Healthcare Stocks That Fared Well in 2020 Amid the Pandemic
by Zacks Equity Research
We take a sneak peek into five healthcare stocks that have performed well in 2020 driven by their improved capabilities to cope with the COVID-19 crisis.